Bryce A. Kerlin, MD

Bryce A. Kerlin, MD is an Investigator in the Center for Clinical & Translational Research at Nationwide Children's Research Institute, Medical Director of the Nationwide Children’s Hospital Hemostasis and Thrombosis Center, a member of the Hematology/Oncology/BMT Division, and an Associate Professor of Pediatrics at The Ohio State University College of Medicine. His research is focused on the translational epidemiology of pediatric thrombosis, focusing on the elucidation of biomarkers and clinical characteristics associated with thrombosis, especially in pediatric kidney disease. He actively participates in clinical trials for new treatments in hemostasis and thrombosis, including new medications for hemophilia, von Willebrand disease, and blood clots.

Gender:

• Male

Languages Spoken:

• English

Research Center:

• Center for Clinical and Translational Research
• Hospital-Based Research Faculty

Research Funding*:

• Patient and Family Support Group for Hemophilia Clinic, Hemophilia Foundation of Michigan/Cascade Hemophilia Consortium

Medical School

• Medical College of Wisconsin

Post Doctoral

• Blood Research Institute: The Blood Center of Southeastern Wisconsin

Fellowship

• Medical College of Wisconsin and Children’s Hospital of Wisconsin

Undergraduate School

• Purdue University

Medical School

• Medical College of Wisconsin
  Date Completed: 05/18/1996

Internship

• Phoenix Children's Hospital
  Date Completed: 06/30/1997

Residency

• Phoenix Children's Hospital
  Date Completed: 06/30/1999

Fellowship

• Medical College of Wisconsin
  Date Completed: 06/30/2002

Department:

• Pediatrics

Section:

• Hematology/Oncology

Speciality:

• Pediatric Hematology Oncology
  

Date of Appointment at Nationwide Children’s Hospital:

• 12/31/2004

2005–present

• Director of Hematology, Nationwide Children's Hospital

2004–present

• Tumor Board,  Nationwide Children's Hospital

2004–present

• Pharmacy & Therapeutics, Nationwide Children's Hospital

2004–present

• Director, Nationwide Children's Hospital Hemophilia & Bleeding Disorders Program

2004–present

• Board Member, Ohio Bleeding Disorders Council
  

2004–2004

• Pharmacy & Therapeutics Committee, Children's Hospital of San Diego

2002–2004

• Medical Director, Hemophilia Association of San Diego County

2002–2004

• Transfusion Medicine Committee, Children's Hospital of San Diego

2002–2004

• Cancer Committee, Children's Hospital of San Diego

2002–2004

• Director, San Diego Regional Pediatric Hemophilia Program

2002–2004

• Tumor Board; Children's Hospital of San Diego

1999–2002

• Tumor Board; Children's Hospital of Wisconsin

1998–1999

• Director, Resident as Teacher Program; Phoenix Children’s Hospital/Maricopa Medical Center Pediatric Residency Program

1998–1999

• Chairman, House Staff Social Committee; Phoenix Children’s Hospital/Maricopa Medical Center Pediatric Residency Program

• Setty BA, O’Brien SH, KERLIN BA. 2012. Pediatric Venous Thromboembolism in the United States: A Tertiary Care Complication of Chronic Diseases.  Pediatric Blood & Cancer. Vol. 59, no. August: 258-264. PubMed ID: 22038730
• Sladky JL, Klima J, Grooms L, KERLIN BA, O'Brien SH. 2012. The PFA-100® does not predict delta-granule platelet storage pool deficiencies.  Haemophilia. Vol. 18, no. 4. (July): 626-629. PubMed ID: 22226191
• KERLIN BA. 2012. Current and Future Management of Pediatric Venous Thromboembolism.  Am J Hematol. Vol. 87, no. May: S68-S74. PubMed ID: 22367975
• KERLIN BA Ayoob R, Smoyer WE. 2012. Epidemiology and Pathophysiology of Nephrotic Syndrome-Associated Thromboembolic Disease.  Clin J Am Soc Nephrol. Vol. 7, no. March: 513-520.
• Kerlin,Bryce,A. 2011. Pulmonary morbidity of catheter-related pediatric venous thromboembolism: Old problem, new worry.  CRITICAL CARE MEDICINE. Vol. 39, no. 5. (May): 1234-1235.
• Karsies TJ, Nicol KK, Galantowicz ME, Stephens JA, KERLIN BA. 2010. Thrombotic Risk of Recombinant Factor Seven in Pediatric Cardiac Surgery: A Single Institution Experience.  Annals of Thoracic Surgery. Vol. 89, no. 2. (February): 570-577.
• Kerlin,Bryce,A. 2009. Thrombolysis for Pediatric Venous Thromboembolism: Is it Time for a Trial?.  PEDIATRIC BLOOD & CANCER. Vol. 53, no. 6. (December): 920-921.
• KERLIN BA. 2009. Screening for Anemia. In Textbook of Pediatric Care. 1st ed. Edited by McInerny TK, Adam HM, Campbell D, Kamat DK, Kelleher KJ. Elk Grove Village, IL: American Academy of Pediatrics.
• Mast KJ, Nunes ME, Ruymann FB, KERLIN BA. 2009. Desmopressin Responsiveness in Children with Ehlers-Danlos Syndrome Associated Bleeding Symptoms.  British Journal of Haematology. Vol. 144, no. January: 230-233.
• Hyatt SA, Wang W, KERLIN BA, O'Brien S. 2009. Applying Diagnostic Criteria for Type 1 von Willebrand Disease to a Pediatric Population.  Pediatric Blood & Cancer. Vol. 52, no. January: 102-107.
• Klopfenstein KJ, Clayton J, Rosselet R, KERLIN B, Termuhlen A, Gross T. 2009. Prevalence of Abnormal Bone Density of Pediatric Patients Prior to Blood or Marrow Transplant.  Pediatric Blood & Cancer. Vol. 53, no. January: 675-677.
• KERLIN BA, Blatt NB, Fuh B, Zhao S, Lehman A, Blanchong C, Mahan JD, Smoyer WE. 2009. Epidemiology and Risk Factors for Thromboembolic Complications of Childhood Nephrotic Syndrome: A Midwest Pediatric Nephrology Consortuim (MWPNC) Study.  The Journal of Pediatrics. Vol. 155, no. January: 105-110. PubMed ID: 19394032
• KERLIN BA. 2009. Thrombolysis for Pediatric Venous Thromboembolism: Is it Time for a Trial?.  Pediatric Blood & Cancer. Vol. 53, no. January: 920-921.
• Sharathkumar A, Hardesty B, Greist A, Salter J, KERLIN B, Heiman M, Sulkin M, Shapiro A. 2009. Variability in Bleeding Phenotype in Amish Carriers of Hemophilia B with the C31008T Mutation.  Haemophilia. Vol. 15, no. January: 91-100.
• Rose MJ, Nicol KK, Skeens MA, Gross TG, KERLIN BA. 2008. Congenital Amegakaryocytic Thrombocytopenia: the Diagnostic Importance of Combining Pathology with Molecular Genetics.  Pediatric Blood & Cancer. Vol. 50, no. January: 1263-1265.
• Lo W, Zamel K, Ponnappa K, Allen A, Chisolm D, Tang M, KERLIN B, Yeates KO. 2008. The Cost of Pediatric Stroke Care and Rehabilitation.  Stroke. Vol. 39, no. January: 161-165.
• Varga EA, KERLIN BA, Wurster MW. 2008. Social and Ethical Controversies in Thrombophilia Testing and Updates on Genetic Risk Factors for Venous Thromboembolism.  Seminars in Thrombosis and Hemostasis. Vol. 34, no. January: 549-561.
• Davis RL, Mosesson MW, KERLIN BA, Canner JA, Ruymann FB, Brennan SO. 2007. Fibrinogen Columbus: a Novel gamma Gly200Val Mutation Causing Hypofibrinogenemia in a Family with Associated Thrombophilia.  Haematologica. Vol. 92, no. January: 1151-1152.
• Nicol K, Swedan N, Moder P, Kahwash S, Rose M, KERLIN B. 2006. Hemolytic Anemia in a 5-Year-Old Child.  LabMedicine. Vol. 37, no. January: 746-748.
• Savelli SL, Kerlin BA, Springer MA, Monda K, Thornton J, Blanchong CA: Recommendations for Screening for Thrombophilic Tendencies in Teenage Females Prior to Contraceptive Initiation.  Journal of Pediatric and Adolescent Gynecology 19:313-6, 2006. PubMed ID: 16873040
• Savelli SL, KERLIN BA, Springer MA, Monda K, Thornton J, Blanchong CA. 2006. Recommendations for Screening for Thrombophilic Tendencies in Teenage Females Prior to Contraceptive Initiation.  Journal of Pediatric and Adolescent Gynecology. Vol. 19, no. January: 313-316. PubMed ID: 16873040
• Loh KC, Willert J, Meltzer H, Roberts W, KERLIN B, Kadota R, Levy M, White G, Geddis A, Schiff D, Martin L, Yu A, Kung F, Spear MA. 2005. Temozolomide and Radiation for Aggressive Pediatric Central Nervous System Malignancies.  Journal of Pediatric Hematology/Oncology. Vol. 27, no. 5. (January): 254-258.
• KERLIN BA, Cooley BC, Isermann BH Hernandez I, Sood R, Zogg M, Hendrickson SB, Mosesson MW, Lord S, Weiler H. 2004. Cause-Effect Relation between Hyperfibrinogenemia and Vascular Disease.  Blood. Vol. 103, no. 5. (January): 1728-1734.
• Weiler H, KERLIN B, Lytle MC. 2004. Factor V Leiden Polymorphism Modifies Sepsis Outcome: Evidence from Animal Studies.  Critical Care Medicine. Vol. 32, no. 5 Supplement. (January): S233-S238. PubMed ID: 15118524
• KERLIN BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, Joyce DE, Weiler H, Dhainaut J-F. 2003. Survival Advantage Associated with Heterozygous Factor V Leiden Mutation in Patients with Severe Sepsis and in Mouse Endotoxemia.  Blood. Vol. 102, no. 9. (January): 3085-3092.
• Greenbaum LA, KERLIN BA, Van Why S, Punzalan RC, Trost BA, Pan CG, Scott JP. 2003. Concurrent Poststreptococcal Glomerulonephritis and Autoimmune Hemolytic Anemia.  Pediatric Nephrology. Vol. 18, no. 12. (January): 1301-1303.
• Weiler H, Lindner V, KERLIN B, Isermann BH, Hendrickson SB, Cooley BC, Meh DA, Mosesson MW, Shworak NW, Post MJ, Conway EM, Ulfman LH, von Andrian UH, Weitz JI. 2001. Characterization of a Mouse Model for Thrombomodulin Deficiency.  Arteriosclerosis, Thrombosis, and Vascular Biology. Vol. 21, no. 9. (January): 1531-1537.
• Woods G, KERLIN BA. Childhood Venous Thromboembolism. In Succinct Pediatrics. Edited by Feld L and Mahan JD.

• Listed, Best Doctors in America